Codexis Inc Stock Price, News & Analysis

Codexis (NASDAQ: CDXS) signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California to expand internal GMP production capabilities.

The multi-purpose site will enable GMP manufacturing of siRNA and other oligonucleotides using the company's ECO Synthesis platform, start modifications in early 2026, and can be adapted to scale production of purified enzymes that support the platform. The company said the facility will support early clinical trial manufacturing and provide flexible capacity for evolving business needs.

Codexis (NASDAQ: CDXS) reported Q3 2025 results and a business update on Nov 6, 2025. Key items include a $37.8M Supply Assurance Agreement with Merck (cash expected by year‑end), organizational changes including a CEO transition, elimination of 46 positions (~24% workforce) and an expected $3.5M charge in Q4 2025. Management said these actions extend the company’s cash runway . Financials: Q3 revenue $8.6M versus $12.8M a year ago; product gross margin 64%; R&D $13.9M; SG&A $11.2M; net loss $19.6M. Cash and short‑term investments were $58.7M as of Sept 30, 2025.

Codexis (NASDAQ: CDXS) and Nitto Denko Avecia announced an evaluation agreement dated Oct. 29, 2025 for Codexis' ECO Synthesis® Manufacturing Platform. Under the agreement, Nitto Denko Avecia will evaluate the enzyme‑catalyzed ECO Synthesis approach that replaces traditional solid‑phase oligonucleotide synthesis.

The collaboration is intended to enable future licensing discussions and broader adoption of the platform, and to explore scalable, sustainable manufacturing for therapeutic siRNA by combining Codexis' enzymatic technology with Nitto Denko Avecia's CDMO expertise.

Codexis (NASDAQ: CDXS) will report third quarter 2025 financial results on Thursday, November 6, 2025, after market close. Management will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and provide a business update.

Investors can access the live webcast on the Codexis Investor Relations website; the webcast will be archived for 90 days. A telephone replay will be available for 48 hours with access ID 13726635.

Codexis (NASDAQ:CDXS), a provider of enzymatic solutions for therapeutic manufacturing, announced its participation in the upcoming Cantor Global Healthcare Conference. The event will take place from September 3-5, 2025, in New York.

The company's management will engage in a fireside chat on September 4, 2025, at 3:55 pm ET. Investors can access a live webcast through Codexis's investor relations website, with a replay available for 90 days after the event.

Codexis (NASDAQ: CDXS) reported strong Q2 2025 financial results with revenue of $15.3 million, surpassing analyst estimates of $14.1 million. The company strengthened its cash position by raising $27.3 million through ATM facility and Innovatus loan to support its ECO Synthesis platform expansion.

Key financial metrics include a 72% product gross margin (up from 45% in Q2 2024), R&D expenses of $13.8 million, and a net loss of $13.3 million ($0.16 per share). The company ended Q2 with $66.3 million in cash and equivalents.

Notably, Codexis' ECO Synthesis platform was featured in six presentations at TIDES USA, including three from CDMO collaborators, demonstrating strong external validation. The company now has over 30 opportunities in various stages and expects to achieve pilot-scale production of GLP-grade siRNA material in 2025.

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutic manufacturing, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, after market close.

The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates. Investors can access the webcast through Codexis' Investor Relations website, where it will remain available for 90 days. For the live call, participants can dial 877-705-2976 (domestic) or 201-689-8798 (international).

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place from June 3-5, 2025 in New York.

The company's management will engage in a fireside chat on June 4, 2025, at 3:10 pm ET. Investors can access a live webcast of the presentation through Codexis's investor relations website, with a replay available for 90 days after the event.

Codexis (NASDAQ: CDXS) reported Q1 2025 financial results with total revenues of $7.5 million, down from $17.1 million in Q1 2024. The company secured its first revenue-generating contract for ECO Synthesis™ manufacturing services and maintained a strong cash position of $59.8 million. Net loss widened to $20.7 million ($0.25 per share) compared to $11.5 million ($0.16 per share) in Q1 2024. Product gross margin improved to 55% from 49% year-over-year. The company reiterated its 2025 guidance with expected total revenues of $64-68 million and anticipates reaching positive cash flow by the end of 2026. Notable achievements include successful development of first-generation ECO Synthesis enzymes and new board appointments. The company expects to achieve pilot scale production of GLP-grade siRNA material and sign a GMP scale-up partner by end of 2025.